Use of atypical antipsychotics in children: Balancing safety and effectiveness

American Family Physician

Volumn 81, Issue 5, 2010, Pages 585-588

  Kohlstadt, Ingrid ^a   Vitiello, Benedetto ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AUTISM; AUTOMUTILATION; BIPOLAR MANIA; CHILD; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; METABOLIC DISORDER; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PROLACTIN BLOOD LEVEL; QT PROLONGATION; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT INDICATION; WEIGHT GAIN;

EID: 77949692980     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (9)

1. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-622.
2. Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629-635.
3. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study [published correction appears in Am J Psychiatry. 2008;165(11):1495]. Am J Psychiatry. 2008;165(11):1420-1431.
4. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):A42.
5. Kohlstadt I. Scientific Evidence for Musculoskeletal, Bariatric, and Sports Nutrition. Boca Raton, Fla.: Taylor & Francis; 2006:621.
6. Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics. 2009;124(3):e362-e370.
7. Correll CU. Effect of hyperprolactinemia during development in children and adolescents. J Clin Psychiatry. 2008;69(8):e24.
8. U.S. Food and Drug Administration. July 20, 2009 meeting of the Psychopharmacologic Drugs Advisory Committee. http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ PsychopharmacologicDrugsAdvisoryCommittee/ucm126199.htm. Accessed October 19, 2009.
9. Kohlstadt I, Rappley M, Robb A, Vitiello B. Atypical antipsychotics in children and adolescents: Balancing safety and efficacy. Audio-Digest Pediatrics. 2009;55(16):1-4.